Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Tries Sales Outsourcing In China

This article was originally published in PharmAsia News

Executive Summary

Pfizer has outsourced part of its medical sales in China in an attempt to cut costs and push its non-core products. NovaMed Pharmaceuticals will exclusively distribute and promote Pfizer's six tumor drugs, namely, Adriamycin, Daunorubicin, Leucovorin, Methotrexate, Estracyt and Farlutal from June, to increase the hospital coverage rate for the drugs by 30 percent to 40 percent. Novamed has developed an entire tumor drug product line and established broad-ranging relationships with tumor drug distributors across the nation. In addition, the company participates in hospital drug tenders and drug pricing, with plans to introduce more MNC tumor drugs to China. This unique model shows that pharmaceutical MNCs are leveraging on outsourcing to penetrate the country's distribution network. (Click here for more - Chinese Language)

You may also be interested in...

Sweden’s Orexo Forms Partnership With Shanghai’s NovaMed To Enter Chinese Oncology Market

SHANGHAI - Swedish pharmaceutical firm Orexo has signed an agreement with Shanghai-based NovaMed for the distribution of Orexo's cancer pain treatment Abstral (fast-dissolving fentanyl) in China

NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News

Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.

Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers

“Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFl isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts